Developing peptide-based inhibitors of amylin aggregation as a novel treatment for type 2 diabetes
Human islet amyloid polypeptide (hIAPP), also known as amylin, is the main constituent of the amyloid deposits present in approximately 95% of people with type 2 diabetes. Amylin aggregates into oligo-/polymeric sheet structures which are considered to be cytotoxic to pancreatic -cells. Inhibiting t...
| Main Author: | |
|---|---|
| Other Authors: | |
| Published: |
Lancaster University
2017
|
| Online Access: | https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.727170 |